Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
Nurix Therapeutics (NRIX) announced a webcast scheduled for December 9, 2024, at 8:15 p.m. PT to present new clinical data from its ongoing Phase 1a/1b trial of BTK degrader NX-5948. The presentation will feature Dr. Nirav N. Shah from the Medical College of Wisconsin, who will discuss trial results in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Company executives will outline the clinical development strategy for NX-5948 in both oncology and autoimmune indications, along with updates on other clinical stage programs.
Nurix Therapeutics (NRIX) ha annunciato un webcast programmato per il 9 dicembre 2024, alle 20:15 PT, per presentare nuovi dati clinici dal suo ongoing trial di Fase 1a/1b del degrader BTK NX-5948. La presentazione vedrà la partecipazione del Dr. Nirav N. Shah del Medical College of Wisconsin, che discuterà i risultati dello studio su pazienti con leucemia linfatica cronica (CLL) in recidiva/refrattaria. I dirigenti dell'azienda delineeranno la strategia di sviluppo clinico per NX-5948, sia in oncologia che in indicazioni autoimmuni, insieme agli aggiornamenti su altri programmi in fase clinica.
Nurix Therapeutics (NRIX) anunció una transmisión web programada para el 9 de diciembre de 2024, a las 8:15 p.m. PT, para presentar nuevos datos clínicos de su ensayo en Fase 1a/1b del degradador de BTK NX-5948. La presentación contará con el Dr. Nirav N. Shah del Medical College of Wisconsin, quien discutirá los resultados del ensayo en pacientes con leucemia linfática crónica (CLL) en recaída/refractaria. Los ejecutivos de la empresa esbozarán la estrategia de desarrollo clínico para NX-5948 en oncología y en indicaciones autoinmunitarias, además de actualizaciones sobre otros programas en etapa clínica.
Nurix Therapeutics (NRIX)는 2024년 12월 9일 오후 8시 15분 PT에 BTK 분해제 NX-5948의 진행 중인 1a/1b 단계 시험에서 새로운 임상 데이터를 발표하는 웹캐스트를 예정하고 있음을 발표했습니다. 발표에는 위스콘신 의과대학의 닐라브 N. 샤 박사가 참여하여 재발/불응성 만성 림프구성 백혈병(CLL) 환자의 시험 결과에 대해 논의할 예정입니다. 회사 경영진은 NX-5948의 임상 개발 전략을 종양학 및 자가면역 적응증 모두에서 설명하고, 다른 임상 단계 프로그램에 대한 업데이트를 제공합니다.
Nurix Therapeutics (NRIX) a annoncé un webcast prévu pour le 9 décembre 2024 à 20h15 PT pour présenter de nouvelles données cliniques de son essai de Phase 1a/1b sur le dégradeur BTK NX-5948. La présentation mettra en vedette le Dr. Nirav N. Shah du Medical College of Wisconsin, qui discutera des résultats de l'essai chez des patients atteints de leucémie lymphoïde chronique (LLC) en rechute/réfractaire. Les dirigeants de l'entreprise exposeront la stratégie de développement clinique pour NX-5948, tant en oncologie que dans les indications auto-immunes, ainsi que des mises à jour sur d'autres programmes en phase clinique.
Nurix Therapeutics (NRIX) hat ein Webcast für den 9. Dezember 2024 um 20:15 Uhr PT angekündigt, um neue klinische Daten aus seiner laufenden Phase 1a/1b-Studie des BTK-Degradators NX-5948 zu präsentieren. Der Vortrag wird Dr. Nirav N. Shah vom Medical College of Wisconsin einschließen, der die Studienergebnisse bei Patienten mit rezidivierender/refraktärer chronischer lymphatischer Leukämie (CLL) erörtern wird. Die Unternehmensführung wird die klinische Entwicklungsstrategie für NX-5948 sowohl in der Onkologie als auch in autoimmunen Indikationen umreißen sowie Aktualisierungen zu anderen klinischen Programmen geben.
- None.
- None.
SAN FRANCISCO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a live webcast to review new clinical data from the ongoing Phase 1a/1b clinical trial of its Bruton’s tyrosine kinase (BTK) degrader program NX-5948, and provide a corporate update, at 8:15 p.m. PT (11:15 p.m. ET) on Monday, December 9, 2024.
The webcast will feature a presentation by guest speaker and clinical study investigator Nirav N. Shah, M.D., M.S.H.P., Associate Professor of Medicine, Division of Hematology and Oncology at the Medical College of Wisconsin, who will present clinical data from the ongoing Phase 1a/1b trial of NX-5948 in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, Paula G. O’Connor, M.D., Nurix’s chief medical officer, and Gwenn M. Hansen, Ph.D., Nurix’s chief scientific officer, will outline Nurix’s clinical development strategy for NX-5948 in both oncology and autoimmune indications and provide an overview of Nurix’s other clinical stage programs.
Webcast details
Date and time: Monday, December 9, 2024, 8:15 p.m. PT (11:15 p.m. ET)
Access Details: The live webcast and subsequent archived replay will be available in the Investors section of the Nurix website under Events and Presentations.
About NX-5948
NX-5948 is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK. NX-5948 is designed to specifically eliminate BTK, a key growth signaling protein in B cells, through degradation by the ubiquitin proteasome system of the cell. NX-5948 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies. Nurix has previously reported that NX-5948 is highly potent against a range of tumor cell lines that are resistant to current BTK inhibitor therapies, an important consideration in heavily pretreated CLL/SLL patient populations. Additional information on the ongoing clinical trial can be accessed at clinicaltrials.gov (NCT05131022).
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Forward-Looking Statements
This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding the planned timing for the provision of updates and findings from Nurix’s clinical trials. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions regarding the future of Nurix’s business, its preclinical and clinical results, future conditions and other factors Nurix believes are appropriate in the circumstances. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) the timing and results of Nurix’s clinical trials; (ii) the impact of macroeconomic conditions and global events on Nurix’s business, clinical trials and financial condition; and (iii) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal quarter ended August 31, 2024, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
When will Nurix Therapeutics (NRIX) present the Phase 1 data for NX-5948?
What is the focus of Nurix Therapeutics' (NRIX) NX-5948 clinical trial?
Who will present the clinical data for Nurix Therapeutics' (NRIX) NX-5948 trial?
